Skip to main content

Table 1 Summary of the immune-related analysis

From: Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report

Date

 

Immune-related analysis

December 2010 (Dec-2010)

biopsy

IHC: MART-1/Melan-A +; S-100 +; gp100/HMB-45 +

 

November 2011

surgery

IHC: MART-1/Melan-A +; S-100 +; gp100/HMB-45 +

 

January 2012 (Jan-2012)

sunitinib

 

Immunological monitoring:

April 2012

surgery

IHC: MART-1/Melan-A -; S-100 +; gp100/HMB-45 +; CD3 +; CD8 +

• Frequency of immunosuppressive cells and CD3+ T cell function (Figure 4)

May 2012/April 2013

sunitinib*

 

• Presence of Melan-A/MART-1 specific CD8+ T cells (Figure 3)

  1. Abbreviations: IHC, immunohistochemistry.
  2. Note: *stopped many times due to toxicity with evidence of disease progression following treatment interruption and new response after restoring treatment.